Cyrus Biotechnology Inc. has selected CYR-212, an engineered next-generation reduced-immunogenicity and half-life extended immunoglobulin G (IgG) protease, as a clinical development candidate for ...

2024年最大创新药领域M&A产品Povetacicept亚洲权益之争，终于尘埃落定。

Although the age of onset of lupus is typically between 15 and 44 years old, up to 25% of people diagnosed with systemic lupus erythematosus (SLE) have late-onset lupus. Lupus is most commonly ...

Reduced commitment into the B-cell lineage is not due to an intrinsic haematopoietic stem cell defect, but likely to a non-permissive bone marrow niche in AAV. Low BAFF-receptor expression on B cells ...

is a dual antagonist of the B cell activating factor (BAFF) and a proliferation-inducing ligand that targets systemic lupus erythematosus, glomerulonephritis and cytopenia; and acazicolcept (ALPN-101) ...

Signaling through BAFF-R and BCMA increases the levels of the ... clinical trials and appear well tolerated. Their efficacy in SLE is unknown at present. [58–59] ...

Systemic lupus erythematosus (SLE) is an autoimmune disease with considerable ... A study now shows that heightened extrafollicular B cells and anti-BAFF therapy are linked to inferior responses ...

Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior ... CTLA4 ...

Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior ... CTLA4 ...

Systemic Lupus Erythematosus (SLE), commonly called lupus, is an autoimmune disease that occurs when the ... FABP4, FASLG, IGFBP-2, SELE, and TNFSF13B/BAFF. Examining the renal expression of these ...

Success in cancer treatment over the last four decades has ranged from improvements in classical drug therapy to immune oncology. Anti-cancer drugs have also often proven beneficial for the treatment ...